Alvotech, a global biotech company, has announced a new supply and commercialization agreement with Advanz Pharma for AVT10, their biosimilar candidate to Cimzia® (certolizumab pegol). This marks a significant step as it is the only biosimilar referencing Cimzia® currently under development worldwide. The reference product, Cimzia®, is widely used for treating chronic rheumatic diseases, particularly among women of childbearing age. The agreement aims to expand access to high-quality biologics for patients in Europe and is a continuation of the strategic partnership between Alvotech and Advanz Pharma. The companies plan to launch their first biosimilars in Europe in the fourth quarter of 2025. Cimzia® achieved worldwide sales of $2.3 billion in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.